NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT03850795 2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
Phase 3 Terminated
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed